Reducing phaco-induced apoptosis

Article

Cell apoptosis caused by free-radical formation during phacoemulsification can be mediated by the introduction of ascorbic acid, according to a study published in the December 2008 issue of the Journal of Cataract & Refractive Surgery.

Cell apoptosis caused by free-radical formation during phacoemulsification can be mediated by the introduction of ascorbic acid, according to a study published in the December 2008 issue of the Journal of Cataract & Refractive Surgery.

Naphtali Savion, PhD of Tel-Aviv University, Israel and colleagues assessed cell apoptosis in bovine corneal endothelial cells (CECs), which were cultured on gas-permeable flexible membranes, and then exposed to phacoemulsification. As a control, the researchers also examined cell apoptosis in CECs exposed to hydrogen peroxide for a period of 48 hours.

The researchers found that cell apoptosis increased from 45±12 apoptic nuclei per square millimetre before phacoemulsification to 334±29 48 hours postoperatively. Following 48 hours' exposure to hydrogen peroxide, apoptosis was 345±6 (H2O2 concentration, 50 µM) and 376±1 (H2O2 concentration, 100 µM). Adding ascorbic acid decreased the mean 48-hour post-phaco apoptosis level to 219±15 (ascorbic acid concentration, 1 mM) and 130±29 (ascorbic acid concentration, 10 mM), although applying shear forces up to 2000 seconds1 for 60 minutes did not alter the rate of apoptosis.

The researchers concluded that the increased rate of cell apoptosis that results from phacoemulsification is likely to be caused by free radical formation, and can therefore be modified through the application of ascorbic acid.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.